Ammonia N 13 - 2007 FDA approvals

Drug: Ammonia N 13
Indication: PET scanning
Company: Feinstein
Approval Date: August 27, 2007

Scoop: Feinstein's Ammonia N 13 is a radiopharmaceuticals that allows physicians to get a clearer look inside the human body during PET scans. The approval is for PET imaging of the myocardium to diagnose suspected or existing coronary heart disease.

Ammonia N 13 - 2007 FDA approvals
Read more on

Suggested Articles

The drug failed a futility analysis in March, but Biogen resurrected it after factoring in data generated after the cutoff for the interim assessment.

The negative top-line data deal a big blow to the prospects of a drug analysts tipped to achieve blockbuster sales if it cleared phase 3.

Intrepida Bio launched with $9.5 million from Sofinnova and Canaan Partners to develop anti-BAG3 antibodies for the treatment of cancer.